{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:17:24Z","timestamp":1772173044385,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1009295","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000}}],"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"bundesministerium f\u00fcr bildung und forschung","doi-asserted-by":"publisher","award":["01KI2016"],"award-info":[{"award-number":["01KI2016"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>Pre-exposure prophylaxis (PrEP) is an important pillar to prevent HIV transmission. Because of experimental and clinical shortcomings, mathematical models that integrate pharmacological, viral- and host factors are frequently used to quantify clinical efficacy of PrEP. Stochastic simulations of these models provides sample statistics from which the clinical efficacy is approximated. However, many stochastic simulations are needed to reduce the associated sampling error. To remedy the shortcomings of stochastic simulation, we developed a numerical method that allows predicting the efficacy of arbitrary prophylactic regimen directly from a viral dynamics model, without sampling. We apply the method to various hypothetical dolutegravir (DTG) prophylaxis scenarios. The approach is verified against state-of-the-art stochastic simulation. While the method is more accurate than stochastic simulation, it is superior in terms of computational performance. For example, a continuous 6-month prophylactic profile is computed within a few seconds on a laptop computer. The method\u2019s computational performance, therefore, substantially expands the horizon of feasible analysis in the context of PrEP, and possibly other applications.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1009295","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T13:54:53Z","timestamp":1640267693000},"page":"e1009295","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Numerical approaches for the rapid analysis of prophylactic efficacy against HIV with arbitrary drug-dosing schemes"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3740-4450","authenticated-orcid":true,"given":"Lanxin","family":"Zhang","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9525-5281","authenticated-orcid":true,"given":"Junyu","family":"Wang","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6587-6394","authenticated-orcid":true,"given":"Max","family":"von Kleist","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"issue":"1","key":"pcbi.1009295.ref001","doi-asserted-by":"crossref","first-page":"a006841","DOI":"10.1101\/cshperspect.a006841","article-title":"Origins of HIV and the AIDS pandemic","volume":"1","author":"PM Sharp","year":"2011","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"key":"pcbi.1009295.ref002","unstructured":"UNAIDS. FACT SHEET\u2014GLOBAL AIDS UPDATE 2020; 2020. https:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"key":"pcbi.1009295.ref003","doi-asserted-by":"crossref","unstructured":"Stover J, Kelly SL, Mudimu E, Green D, Smith T, Taramusi I, et al. The Risks and Benefits of Providing HIV Services during the COVID-19 Pandemic. MedRXiV (https:\/\/doi.org\/101101\/2021030121252663). 2021;.","DOI":"10.1101\/2021.03.01.21252663"},{"issue":"4","key":"pcbi.1009295.ref004","first-page":"127","article-title":"Investigational Antiretroviral Drugs: What is Coming Down the Pipeline","volume":"25","author":"RM Gulick","year":"2018","journal-title":"Top Antivir Med"},{"issue":"5988","key":"pcbi.1009295.ref005","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1126\/science.1191047","article-title":"HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals","volume":"329","author":"D Trono","year":"2010","journal-title":"Science"},{"issue":"11","key":"pcbi.1009295.ref006","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrmicro3352","article-title":"Eradicating HIV-1 infection: seeking to clear a persistent pathogen","volume":"12","author":"NM Archin","year":"2014","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"pcbi.1009295.ref007","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41591-019-0412-8","article-title":"Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic","volume":"25","author":"M Caskey","year":"2019","journal-title":"Nat Med"},{"issue":"9903","key":"pcbi.1009295.ref008","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0140-6736(13)61998-4","article-title":"Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?","volume":"382","author":"MS Cohen","year":"2013","journal-title":"The Lancet"},{"issue":"27","key":"pcbi.1009295.ref009","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"RM Grant","year":"2010","journal-title":"N Engl J Med"},{"issue":"10246","key":"pcbi.1009295.ref010","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","article-title":"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"396","author":"KH Mayer","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"pcbi.1009295.ref011","doi-asserted-by":"crossref","first-page":"e1006155","DOI":"10.1371\/journal.pcbi.1006155","article-title":"Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes","volume":"14","author":"S Duwal","year":"2018","journal-title":"PLOS Computational Biology"},{"key":"pcbi.1009295.ref012","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3389\/fphar.2019.00199","article-title":"The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis","volume":"10","author":"S Duwal","year":"2019","journal-title":"Front Pharmacol"},{"key":"pcbi.1009295.ref013","unstructured":"Pipeline AR. https:\/\/www.prepwatch.org\/nextgen-prep\/research-pipeline\/;."},{"issue":"1","key":"pcbi.1009295.ref014","doi-asserted-by":"crossref","first-page":"106220","DOI":"10.1016\/j.ijantimicag.2020.106220","article-title":"Long-acting drugs and formulations for the treatment and prevention of HIV infection","volume":"57","author":"C Flexner","year":"2021","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"pcbi.1009295.ref015","doi-asserted-by":"crossref","first-page":"e788","DOI":"10.1016\/S2352-3018(19)30238-3","article-title":"Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline","volume":"6","author":"LE Coelho","year":"2019","journal-title":"The Lancet HIV"},{"issue":"15","key":"pcbi.1009295.ref016","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1056\/NEJM199704103361507","article-title":"Sexual transmission of HIV","volume":"336","author":"RA Royce","year":"1997","journal-title":"N Engl J Med"},{"issue":"1","key":"pcbi.1009295.ref017","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/COH.0000000000000218","article-title":"Statistical issues in trials of preexposure prophylaxis","volume":"11","author":"DT Dunn","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"issue":"6","key":"pcbi.1009295.ref018","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/cpt.1227","article-title":"HIV Antiretroviral Pre-Exposure Prophylaxis: Development Challenges and Pipeline Promise","volume":"104","author":"CW Hendrix","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"pcbi.1009295.ref019","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/nrmicro3471","article-title":"Bottlenecks in HIV-1 transmission: insights from the study of founder viruses","volume":"13","author":"SB Joseph","year":"2015","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"pcbi.1009295.ref020","doi-asserted-by":"crossref","first-page":"e1008752","DOI":"10.1371\/journal.pcbi.1008752","article-title":"Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action","volume":"17","author":"P Czuppon","year":"2021","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"pcbi.1009295.ref021","doi-asserted-by":"crossref","first-page":"e1006740","DOI":"10.1371\/journal.pcbi.1006740","article-title":"Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis","volume":"15","author":"S Duwal","year":"2019","journal-title":"PLoS Comput Biol"},{"issue":"2","key":"pcbi.1009295.ref022","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1137\/120876800","article-title":"Stochastic analysis of pre-and postexposure prophylaxis against HIV infection","volume":"73","author":"JM Conway","year":"2013","journal-title":"SIAM Journal on Applied Mathematics"},{"issue":"7","key":"pcbi.1009295.ref023","doi-asserted-by":"crossref","first-page":"e40382","DOI":"10.1371\/journal.pone.0040382","article-title":"Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection","volume":"7","author":"S Duwal","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"pcbi.1009295.ref024","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/psp4.12095","article-title":"Multiscale Systems-Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV-1","volume":"5","author":"S Duwal","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"pcbi.1009295.ref025","article-title":"COVIDStrategyCalculator: A software to assess testing- and quarantine strategies for incoming travelers, contact person management and de-isolation","author":"working group on SARS-CoV-2 Diagnostics at RKI","year":"2021","journal-title":"Patterns (N Y)"},{"issue":"3","key":"pcbi.1009295.ref026","doi-asserted-by":"crossref","first-page":"e1000720","DOI":"10.1371\/journal.pcbi.1000720","article-title":"Drug-class specific impact of antivirals on the reproductive capacity of HIV","volume":"6","author":"M Von Kleist","year":"2010","journal-title":"PLOS Computational Biology"},{"issue":"3","key":"pcbi.1009295.ref027","doi-asserted-by":"crossref","first-page":"e18204","DOI":"10.1371\/journal.pone.0018204","article-title":"HIV quasispecies dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirs","volume":"6","author":"M von Kleist","year":"2011","journal-title":"PlOS ONE"},{"issue":"1","key":"pcbi.1009295.ref028","doi-asserted-by":"crossref","first-page":"e1006740","DOI":"10.1371\/journal.pcbi.1006740","article-title":"Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis","volume":"15","author":"S Duwal","year":"2019","journal-title":"PLOS Computational Biology"},{"issue":"1-2","key":"pcbi.1009295.ref029","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.mbs.2008.03.005","article-title":"The probability of HIV infection in a new host and its reduction with microbicides","volume":"214","author":"HC Tuckwell","year":"2008","journal-title":"Mathematical Biosciences"},{"issue":"2","key":"pcbi.1009295.ref030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0025-5564(97)00094-1","article-title":"Stochastic modeling of the dynamics of CD4+ T-cell infection by HIV and some Monte Carlo studies","volume":"147","author":"WY Tan","year":"1998","journal-title":"Mathematical Biosciences"},{"issue":"17","key":"pcbi.1009295.ref031","doi-asserted-by":"crossref","first-page":"8518","DOI":"10.1128\/JVI.76.17.8518-8513.2002","article-title":"Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection","volume":"76","author":"TC Pierson","year":"2002","journal-title":"Journal of virology"},{"issue":"4","key":"pcbi.1009295.ref032","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1128\/JVI.79.4.2199-2210.2005","article-title":"Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells","volume":"79","author":"Y Zhou","year":"2005","journal-title":"Journal of Virology"},{"issue":"12","key":"pcbi.1009295.ref033","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1073\/pnas.0711372105","article-title":"Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle","volume":"105","author":"AR Sedaghat","year":"2008","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"6510","key":"pcbi.1009295.ref034","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/373117a0","article-title":"Viral dynamics in human immunodeficiency virus type 1 infection","volume":"373","author":"X Wei","year":"1995","journal-title":"Nature"},{"issue":"2","key":"pcbi.1009295.ref035","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/135965350901400212","article-title":"Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir","volume":"14","author":"AR Sedaghat","year":"2009","journal-title":"Antiviral Therapy"},{"issue":"3","key":"pcbi.1009295.ref036","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1086\/525283","article-title":"Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro","volume":"197","author":"KK Koelsch","year":"2008","journal-title":"The Journal of Infectious Diseases"},{"issue":"8","key":"pcbi.1009295.ref037","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1128\/JVI.77.8.5037-5038.2003","article-title":"A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo","volume":"77","author":"M Markowitz","year":"2003","journal-title":"Journal of Virology"},{"issue":"3","key":"pcbi.1009295.ref038","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"TC Chou","year":"2006","journal-title":"Pharmacological Reviews"},{"key":"pcbi.1009295.ref039","volume-title":"Stochastic modelling for systems biology","author":"DJ Wilkinson","year":"2018"},{"key":"pcbi.1009295.ref040","unstructured":"SciPy; 2021. https:\/\/docs.scipy.org\/doc\/scipy\/reference\/generated\/scipy.integrate.solve_ivp.html."},{"issue":"6","key":"pcbi.1009295.ref041","doi-asserted-by":"crossref","first-page":"e1004923","DOI":"10.1371\/journal.pcbi.1004923","article-title":"Stochastic simulation of biomolecular networks in dynamic environments","volume":"12","author":"M Voliotis","year":"2016","journal-title":"PLOS Computational Biology"},{"issue":"33","key":"pcbi.1009295.ref042","article-title":"A report on the natural duration of cancer","author":"M Greenwood","year":"1926","journal-title":"A Report on the Natural Duration of Cancer"},{"issue":"7","key":"pcbi.1009295.ref043","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm1777","article-title":"Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs","volume":"14","author":"L Shen","year":"2008","journal-title":"Nat Med"},{"issue":"12","key":"pcbi.1009295.ref044","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nrmicro2911","article-title":"Animal models for HIV\/AIDS research","volume":"10","author":"T Hatziioannou","year":"2012","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"pcbi.1009295.ref045","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/infdis\/jiw077","article-title":"A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine","volume":"214","author":"ML Cottrell","year":"2016","journal-title":"J Infect Dis"},{"key":"pcbi.1009295.ref046","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1752-0509-7-11","article-title":"A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns","volume":"7","author":"A Bershteyn","year":"2013","journal-title":"BMC Syst Biol"},{"issue":"12","key":"pcbi.1009295.ref047","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1128\/AAC.00741-11","article-title":"Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes","volume":"55","author":"M Frank","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1009295.ref048","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF01457949","article-title":"\u00dcber die analytischen Methoden in der Wahrscheinlichkeitsrechnung","volume":"104","author":"A Kolmogoroff","year":"1931","journal-title":"Mathematische Annalen"},{"issue":"270","key":"pcbi.1009295.ref049","doi-asserted-by":"crossref","first-page":"270ra4","DOI":"10.1126\/scitranslmed.3010298","article-title":"A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge","volume":"7","author":"CD Andrews","year":"2015","journal-title":"Science translational medicine"},{"issue":"8","key":"pcbi.1009295.ref050","doi-asserted-by":"crossref","first-page":"e1005075","DOI":"10.1371\/journal.ppat.1005075","article-title":"Nanoformulations of rilpivirine for topical pericoital and systemic coitus-independent administration efficiently prevent HIV transmission","volume":"11","author":"M Kovarova","year":"2015","journal-title":"PLoS Pathog"},{"issue":"6","key":"pcbi.1009295.ref051","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/ni.3152","article-title":"HIV reservoirs as obstacles and opportunities for an HIV cure","volume":"16","author":"TW Chun","year":"2015","journal-title":"Nature immunology"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1009295","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1009295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T03:02:08Z","timestamp":1674183728000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1009295"}},"subtitle":[],"editor":[{"given":"James R.","family":"Faeder","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":51,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1009295","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.07.22.453374","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,23]]}}}